Lastly, since anti-HER2 monotherapy is not covered by the Korean health insurance system, we evaluated the impact of anti-HER2 therapy on bone health by comparing the occurrence of osteoporosis in patients who were treated with and without anti-HER2 therapy. This evidence concerns the gene ERBB2 and osteoporosis.